Adaptive Other Assets vs Other Current Liab Analysis
ADPT Stock | USD 2.60 0.01 0.38% |
Adaptive Biotechnologies financial indicator trend analysis is way more than just evaluating Adaptive Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptive Biotechnologies is a good investment. Please check the relationship between Adaptive Biotechnologies Other Assets and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
Other Assets vs Other Current Liab
Other Assets vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptive Biotechnologies Other Assets account and Other Current Liab. At this time, the significance of the direction appears to have very week relationship.
The correlation between Adaptive Biotechnologies' Other Assets and Other Current Liab is 0.2. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Adaptive Biotechnologies Corp, assuming nothing else is changed. The correlation between historical values of Adaptive Biotechnologies' Other Assets and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Adaptive Biotechnologies Corp are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Other Assets i.e., Adaptive Biotechnologies' Other Assets and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.2 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Other Assets
Other Current Liab
Most indicators from Adaptive Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. Selling General Administrative is likely to drop to about 57.1 M in 2024. Sales General And Administrative To Revenue is likely to drop to 0.35 in 2024
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 105.0M | 127.4M | 72.5M | 78.9M | Total Revenue | 154.3M | 185.3M | 170.3M | 123.7M |
Adaptive Biotechnologies fundamental ratios Correlations
Click cells to compare fundamentals
Adaptive Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptive Biotechnologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 912.3M | 1.1B | 923.3M | 856.6M | 661.1M | 811.6M | |
Other Current Liab | 12.9M | 25.1M | 25.0M | 28.4M | 22.3M | 19.9M | |
Total Current Liabilities | 78.3M | 105.2M | 113.8M | 109.8M | 88.0M | 84.7M | |
Total Stockholder Equity | 571.0M | 743.3M | 604.0M | 464.2M | 308.4M | 347.0M | |
Other Liab | 226.3M | 163.6M | 98.8M | 184.0M | 211.6M | 125.4M | |
Net Tangible Assets | 440.1M | 614.1M | 476.5M | 338.4M | 389.1M | 205.2M | |
Property Plant And Equipment Net | 60.4M | 139.0M | 172.9M | 164.2M | 120.3M | 108.4M | |
Current Deferred Revenue | 61.0M | 73.3M | 80.5M | 64.1M | 48.6M | 55.7M | |
Net Debt | (60.0M) | (15.6M) | (27.3M) | 18.0M | 164.4M | 172.6M | |
Retained Earnings | (365.5M) | (511.6M) | (718.9M) | (919.1M) | (1.1B) | (1.1B) | |
Accounts Payable | 4.5M | 3.2M | 3.3M | 8.1M | 7.7M | 4.8M | |
Cash | 96.6M | 123.4M | 139.1M | 90.0M | 65.1M | 102.9M | |
Non Current Assets Total | 299.6M | 389.5M | 520.6M | 294.5M | 250.9M | 324.4M | |
Non Currrent Assets Other | 2.9M | 2.7M | 3.0M | 4.5M | (1.5M) | (1.5M) | |
Other Assets | 39.5M | 2.7M | 3.0M | 4.5M | 4.0M | 6.7M | |
Cash And Short Term Investments | 576.9M | 688.3M | 353.1M | 498.2M | 346.4M | 443.1M | |
Net Receivables | 12.7M | 10.0M | 17.4M | 40.1M | 39.0M | 20.4M | |
Common Stock Shares Outstanding | 69.2M | 131.2M | 140.4M | 142.5M | 144.4M | 131.8M | |
Short Term Investments | 480.3M | 564.8M | 214.0M | 408.2M | 281.3M | 340.3M | |
Liabilities And Stockholders Equity | 912.3M | 1.1B | 923.3M | 856.6M | 661.1M | 811.6M | |
Non Current Liabilities Total | 263.0M | 268.0M | 205.4M | 282.7M | 264.8M | 276.3M | |
Capital Surpluse | 935.8M | 1.3B | 1.3B | 1.4B | 1.6B | 910.1M | |
Inventory | 9.1M | 14.1M | 19.3M | 14.5M | 14.4M | 13.2M | |
Other Current Assets | 14.1M | 14.5M | 13.0M | 9.4M | 10.4M | 10.6M | |
Other Stockholder Equity | 23.5M | 1.3B | 1.3B | 1.4B | 1.5B | 865.0M | |
Total Liab | 341.3M | 373.1M | 319.2M | 392.5M | 352.9M | 337.9M | |
Net Invested Capital | 571.0M | 743.3M | 604.0M | 464.2M | 308.4M | 347.0M | |
Property Plant And Equipment Gross | 60.4M | 139.0M | 172.9M | 164.2M | 193.6M | 119.9M | |
Total Current Assets | 612.7M | 726.9M | 402.7M | 562.1M | 410.2M | 487.2M | |
Accumulated Other Comprehensive Income | 671K | 893K | (1.1M) | (4.1M) | 215K | 225.8K | |
Net Working Capital | 534.4M | 621.7M | 288.9M | 452.4M | 322.2M | 402.6M | |
Intangible Assets | 11.9M | 10.2M | 8.5M | 6.8M | 5.1M | 8.2M |
Adaptive Biotechnologies Investors Sentiment
The influence of Adaptive Biotechnologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Adaptive. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Adaptive Biotechnologies' public news can be used to forecast risks associated with an investment in Adaptive. The trend in average sentiment can be used to explain how an investor holding Adaptive can time the market purely based on public headlines and social activities around Adaptive Biotechnologies Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Adaptive Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adaptive Biotechnologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Adaptive Biotechnologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Adaptive Biotechnologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adaptive Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adaptive Biotechnologies' short interest history, or implied volatility extrapolated from Adaptive Biotechnologies options trading.
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Adaptive Stock
0.81 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
0.8 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
0.6 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.6 | ELYM | Eliem Therapeutics Upward Rally | PairCorr |
0.59 | HCWB | HCW Biologics | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.